BU CBRN Protection, TNO Defence, Security and Safety, Rijswijk, The Netherlands.
Sleep. 2011 Aug 1;34(8):1119-25. doi: 10.5665/SLEEP.1174.
Sleep problems are a common phenomenon in most neurological and psychiatric diseases. In Parkinson disease (PD), for instance, sleep problems may be the most common and burdensome non-motor symptoms in addition to the well-described classical motor symptoms. Since sleep disturbances generally become apparent in the disease before motor symptoms emerge, they may represent early diagnostic tools and a means to investigate early mechanisms in PD onset. The sleep disturbance, REM sleep behavior disorder (RBD), precedes PD in one-third of patients. We therefore investigated sleep changes in marmoset monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP), the non-human primate model for idiopathic PD.
Mild parkinsonism was induced in 5 marmoset monkeys (3M/2F) over a 2-week period of subchronic MPTP treatment. Electroencephalograms (EEGs) and electromyograms (EMGs) were recorded weekly. Motor activity and hand-eye coordination were also measured weekly, and any signs of parkinsonism were noted each day. Sleep parameters, motor activity, and performance data before and after MPTP treatment were compared between MPTP-treated marmosets and 4 control marmosets (1M/3F).
MPTP increased the number of sleep epochs with high-amplitude EMG bouts during REM sleep relative to control animals (mean ± SEM percentage of REM 58.2 ± 9.3 vs. 29.6 ± 7.7; P < 0.05). Of all sleep parameters measured, RBD-like measures discriminated best between MPTP-treated and control animals. On the other hand, functional motor behavior, as measured by hand-eye coordination, was not affected by MPTP treatment (correct trials MPTP: 23.40 ± 3.56 vs. control: 36.13 ± 5.88 correct trials; P = 0.32).
This REM sleep-specific change, in the absence of profound changes in wake motor behaviors, suggests that the MPTP marmoset model of PD could be used for further studies into the mechanisms and treatment of RBD and other sleep disorders in premotor symptom PD.
睡眠问题是大多数神经和精神疾病的常见现象。例如,在帕金森病(PD)中,睡眠问题可能是除了众所周知的经典运动症状之外最常见和最具负担的非运动症状。由于睡眠障碍通常在疾病出现运动症状之前就已经出现,因此它们可能代表早期诊断工具,并可用于研究 PD 发病的早期机制。在三分之一的患者中,睡眠障碍——快速眼动睡眠行为障碍(RBD)——先于 PD 出现。因此,我们研究了接受 1-甲基-4-苯基-1,2,3,6-四氢吡啶盐酸盐(MPTP)治疗的猕猴的睡眠变化,MPTP 是特发性 PD 的非人类灵长类动物模型。
在亚慢性 MPTP 治疗的 2 周期间,诱导 5 只猕猴(3 只雄性/2 只雌性)出现轻度帕金森病。每周记录脑电图(EEG)和肌电图(EMG)。每周还测量运动活动和手眼协调能力,并每天注意帕金森病的任何迹象。将 MPTP 治疗前后的睡眠参数、运动活动和性能数据与 4 只对照猕猴(1 只雄性/3 只雌性)进行比较。
MPTP 增加了 REM 睡眠期间高振幅 EMG 发作的睡眠期数量,与对照动物相比(平均±SEM REM 中的睡眠期百分比为 58.2±9.3%比 29.6±7.7%;P<0.05)。在所测量的所有睡眠参数中,RBD 样措施最能区分 MPTP 治疗组和对照组。另一方面,手眼协调测量的功能性运动行为不受 MPTP 治疗的影响(正确试验 MPTP:23.40±3.56 与对照:36.13±5.88 正确试验;P=0.32)。
这种 REM 睡眠特异性变化,而清醒运动行为没有明显变化,表明 PD 的 MPTP 猕猴模型可用于进一步研究 PD 运动前症状中 RBD 和其他睡眠障碍的机制和治疗方法。